Recombinant factor VIIa: Safety and efficacy

Current Opinion in Hematology

Volumn 14, Issue 5, 2007, Pages 504-509

  Goodnough, Lawrence T ^a   Shander, Aryeh S ^b,c  

^a STANFORD UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Bleeding; Efficacy; Recombinant factor VIIa; Safety

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; FRESH FROZEN PLASMA; HEPARIN; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP; WARFARIN;

ARTERY THROMBOSIS; BLEEDING; BLOOD CLOT; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HEART INFARCTION; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; INJURY; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FUNCTION; LUNG EMBOLISM; OCCLUSIVE CEREBROVASCULAR DISEASE; POPULATION RESEARCH; POSTTRAUMATIC COMPLICATION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; STROKE; THROMBOSIS;

ADULT; CONSENSUS; DISSEMINATED INTRAVASCULAR COAGULATION; DRUG ANTAGONISM; DRUG TOXICITY; FACTOR VIIA; HEMOSTASIS; HOSPITALS; HUMANS; PHARMACY AND THERAPEUTICS COMMITTEE; RECOMBINANT PROTEINS; STROKE; VITAMIN K; WARFARIN;

EID: 34748860267     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32826388c3     Document Type: Review

References (40)

1. Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 2002; 42:114-124.
2. Goodnough LT. Experience with recombinant factor VIIa in thrombocytopenic patients. Sem Hematol 2003; 41 (Suppl 1):25-29.
3. Poon MC, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999; 94:3591-3593.
4. White B, McHale J, Ravi N, et al. Successful use of recombinant FVIIa (Novoseven) in the management of intractable postsurgical intra-abdominal haemorrhage. Br J Haematol 1999; 107:677-678.
5. Goodnough LT. Treatment of bleeding in the intensive care unit. In Recombinant factor VIIa: potential treatment of critical bleeding in the future ICU (Goodnough LT, guest editor). Int Care Med 2002; 28:A5.
6. Martinowitz U, Kenet G, Segale N, et al. Recombinant activated factor VII in adjunctive hemorrhage control in trauma. J Trauma 2001; 51:431-439.
7. Chuansumrit A, Treepongkaruna S, Phuapradit P. Successful invasive procedures in children with liver failure using recombinant factor VIIa. Hemophilia 2000; 6:348.
8. Levy M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding. Crit Care Med 2005; 33:883-890.
9. Goodnough LT, Lublin DM, Zhang L, et al. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004; 44:1325-1331.
10. Park P, Fewel ME, Garton HJ, et al. Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophiliac neurosurgical patients. Neurosurgery 2003; 53:34-39.
11. Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind, placebo-controlled randomized trial. Lancet 2003; 361:201-205.
12. Clark AD, Gordon WC, Walker ET, Tait RC. 'Last ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang 2004; 86:120-124.
13. Karkouti K, Beattie WC, Wijeysundera DN, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery. Transfusion 2005; 45:26-34.
14. Karkouti K, Yau TM, Riazi S, et al. Determinants of complications with recombinant factor VIIa for refractory blood loss in cardiac surgery. Can J Anaesth 2006; 53:802-809.
15. McCall P, Story DA, Karapillai D. Audit of factor VIIa for bleeding resistant to conventional therapy following complex cardiac surgery. Can J Anaesth 2006; 53:926-933.
16. Von Heyman C, Redlich U, Jain U, et al. Recombinant activated factor VII for refractory bleeding after cardiac surgery. Crit Care Med 2005; 33:2241-2246.
17. Diprose P, Herbertson MJ, O'Shaughnessy D, Gill RS. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex noncoronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth 2005; 95:596-602.
18. Ekert H, Brizard C, Eyers R, et al. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coag Fibrin 2006; 17:389-395.
19. Boffard KD, Riou B, Warren B, et al. Adjunctive therapy for bleeding control in severely injured trauma patients. J Trauma 2005; 59:8-15.
20. O'Connell NM, Perry DJ, Hodgson AJ, et al. Recombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion 2003; 43:1711-1716.
21. Mariani G, Testa MG, Di Paolantonio T, et al. Use of recombinant, activated Factor VII in the treatment of congenital factor VII deficiencies. Vox Sang 1999; 77:131-136.
22. Wong WY, Huang WC, Miller R, et al. Clinical efficacy and recovery levels of recombinant FVIIa (Novoseven) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiency. Haemophilia 2000; 6:50-54.
23. Deveras RAE, Kessler CM. Recombinant factor VIIa (rFVIIa) successfully and rapidly corrects the excessively high international normalized ratio (INR) and prothrombin times induced by warfarin. Blood 2000; 96:638a.
24. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Int Med 2002; 137:884-888.
25. Lin J, Hanigan WC, Tarantino M, Wang J. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg 2003; 98:737-740.
26. Brody DL, Aiyagari V, Shackleford AM, Diringer MN. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2005; 2:263-267.
27. Bernstein DE, Jeffers L, Erhardtsen E, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997; 113:1930-1937.
28. Jeffers L, Chalasani N, Balart L, et al. Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology 2002; 123:118-126.
29. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized double-blind trial. Gastroenterology 2004; 127:1123-1130.
30. Lodge JPA, Jonas S, Malago M, et al. Recombinant coagulation factor VIIa in major liver resection. Anesth 2005; 102:269-275.
31. Mayer SA, Brun NL, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352:777-785.
32. O'Connell NM. Factor XI deficiency - from molecular genetics to clinical management. Blood Coag Fibrin 2003; 14 (Suppl 1):S59-S64.
33. Pickard JD, Kirkpatrick PJ, Melsen T, et al. Potential role of Novoseven in the prevention of rebleeding following aneurismal subarachnoid haemorrhage. Blood Coag Fibrin 2000; 11 (suppl):S117-S120.
34. Laffan M, O'Connell NM, Perry DJ, et al. Analysis and results of the recombinant factor VIIa extended use registry. Blood Coag Fibrin 2003; 14 (suppl):S35-S38.
35. O'Connell KA, Wood SS, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295:293-298. A review of adverse events reported to the US Food and Drug Administration in patients receiving human rFVIIa in nonapproved settings.
36. Levy J, Fingerhut A, Brott T, et al. Recombinant factor VIIa in patients with coagulopathy: review of safety. Transfusion 2006; 46:919-933. A review of adverse events tabulated in controlled clinical trials in patients receiving human rFVIIa.
37. Warren O, Mandel K, Hadjianastassiou V, et al. Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg 2007; 83: 707-714.
38. Bui JD, Despotis GD, Trulock EP, et al. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac and Cardiovasc Surgery 2002; 124:852-854.
39. Shander A, Goodnough LT, Ratko T, et al. Consensus recommendations for the off-label use of recombinant human factor VIIa (Novoseven) therapy. Pharmacol Therapeutics 2005; 30:644-658.
40. Matthew P, Simon TL, Hunt KE, Crookston KP. How we manage requests for recombinant Factor VIIa. Transfusion 2007; 47:8-17.